COLLEGIUM PHARMACEUTICAL, INC (COLL) Form 8-K — Aug 6, 2026
Collegium Pharmaceutical reported Q2 2026 product revenues of $199.9 million, up 6% year-over-year, and adjusted EBITDA of $113.8 million, up 8% year-over-year. The company also completed the acquisition of AZSTARYS from Corium Therapeutics in May 2026, generating $12.9 million in net revenue from the partial quarter of sales. The pain portfolio generated $140.9 million in net revenues, down 9% year-over-year, with Belbuca up 10% year-over-year and Xtampza ER and Nucynta franchise down 14% and 24% respectively.
Key figures
- Revenue
- 199.9
- Revenue Yoy
- 6
- Cash Position
- 129.5
- Adjusted Ebitda
- 113.8
- Belbuca Revenue
- 57.7
- Azstarys Revenue
- 12.9
- Jornay Pm Revenue
- 46.1
- Product Revenues
- 199.9
- Xtampza Er Revenue
- 45
- Operating Cash Flow
- 71.3
- Shares Outstanding
- 32460783
- Pain Portfolio Revenue
- 140.9
- Adjusted Ebitda Guidance
- 445 to 470 million
- Azstarys Revenue Guidance
- 65 to 75 million
- Jornay Pm Revenue Guidance
- 190 to 200 million
- Net Debt To Adjusted Ebitda
- 2.1
- Nucynta Franchise Revenue
- 35.2
- Product Revenues Guidance
- 825 to 855 million
- Adjusted Operating Expenses
- 66.6
- Adjusted Operating Expenses Yoy
- 8
Price after filing
Close on the filing date to close N calendar days later (from $35.73). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.